Document is current

Any future updates will be listed below

Development of 90Y-DOTA-nimotuzumab Fab fragment for radioimmunotherapy

Crossref DOI link: https://doi.org/10.1007/s10967-014-3402-9

Published Online: 2014-08-24

Published Print: 2014-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark